Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 11/20 | 0.51 |
| ▸ | MAPK13 | O15264 | 10/20 | 0.51 |
| ▸ | MAPK12 | P53778 | 10/20 | 0.51 |
| ▸ | MAPK11 | Q15759 | 10/20 | 0.51 |
| ▸ | GRM4 | Q14833 | 4/20 | 0.40 |
| ▸ | GRM1 | Q13255 | 3/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | PTK6 | Q13882 | 1/20 | 0.38 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.35 |
| ▸ | CCNK | O75909 | 1/20 | 0.35 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.35 |
| ▸ | CDK2 | P24941 | 1/20 | 0.35 |
| ▸ | CDK9 | P50750 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7083149 | 1.00 | MAPK14 (0.51) | MAPK14MAPK13MAPK12MAPK11GRM4 | |
| SCHEMBL7079620 | 0.90 | MAPK14 (0.48) | MAPK14MAPK13MAPK12MAPK11GRM4 | |
| SCHEMBL7079618 | 0.90 | MAPK14 (0.48) | MAPK14MAPK13MAPK12MAPK11GRM4 | |
| SCHEMBL7082272 | 0.85 | MAPK13 (0.53) | MAPK14MAPK13MAPK12MAPK11GRM1 | |
| SCHEMBL7082270 | 0.85 | MAPK13 (0.53) | MAPK14MAPK13MAPK12MAPK11GRM1 | |
| SCHEMBL7080485 | 0.85 | MAPK14 (0.53) | MAPK14MAPK13MAPK12MAPK11GRM4 | |
| SCHEMBL7079647 | 0.85 | MAPK14 (0.65) | MAPK14MAPK13MAPK12MAPK11GRM4 | |
| SCHEMBL7076418 | 0.83 | MAPK14 (0.53) | MAPK14MAPK13MAPK12MAPK11GRM1 | |
| SCHEMBL7076419 | 0.83 | MAPK14 (0.53) | MAPK14MAPK13MAPK12MAPK11GRM1 | |
| SCHEMBL7079847 | 0.81 | MAPK14 (0.54) | MAPK14MAPK13MAPK12MAPK11GRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030073832-A1 | Novel aminophenyl ketone derivatives | LEO PHARMACEUTICAL PRODUCTS LTD. A/S (DK) | 2003-04-17 | — | — | US | claimed |
| US-20030073832-A1 | Novel aminophenyl ketone derivatives | LEO PHARMACEUTICAL PRODUCTS LTD. A/S (DK) | 2003-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030073832-A1 | Novel aminophenyl ketone derivatives | MAPKAPK2, MAP3K2, MAP3K1 | MAPK14 28/4885MAPK13 33/4885MAPK12 36/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.